- Previous Close
0.00 - Open
21.06 - Bid 17.82 x 39400
- Ask 18.18 x 36900
- Day's Range
21.06 - 21.06 - 52 Week Range
12.94 - 24.80 - Volume
250 - Avg. Volume
144 - Market Cap (intraday)
1.585B - Beta (5Y Monthly) -0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-0.20 - Earnings Date May 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
www.bioarctic.seRecent News: BRCTF
View MorePerformance Overview: BRCTF
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BRCTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BRCTF
View MoreValuation Measures
Market Cap
1.59B
Enterprise Value
1.54B
Trailing P/E
--
Forward P/E
13.18
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
62.62
Price/Book (mrq)
18.01
Enterprise Value/Revenue
59.90
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-68.81%
Return on Assets (ttm)
-12.29%
Return on Equity (ttm)
-18.24%
Revenue (ttm)
257.35M
Net Income Avi to Common (ttm)
-177.08M
Diluted EPS (ttm)
-0.20
Balance Sheet and Cash Flow
Total Cash (mrq)
512.93M
Total Debt/Equity (mrq)
6.06%
Levered Free Cash Flow (ttm)
-558.52M